Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
HUNT DOUGLAS M | See Remarks | May 03 | Sale | 2.31 | 438 | 1,012 | 81,900 | May 05 05:36 PM | NOUGUES MAXIMO F | Chief Financial Officer | May 03 | Sale | 2.34 | 165 | 386 | 121,228 | May 04 06:46 PM | NOUGUES MAXIMO F | Chief Financial Officer | May 03 | Sale | 2.34 | 165 | 386 | 121,228 | May 04 06:44 PM | NOUGUES MAXIMO F | Chief Financial Officer | May 03 | Sale | 2.34 | 165 | 386 | 121,228 | May 04 06:43 PM | AUERBACH ALAN H | President and CEO | May 03 | Sale | 2.32 | 1,263 | 2,930 | 6,345,292 | May 04 06:37 PM | HUNT DOUGLAS M | See Remarks | Apr 04 | Sale | 3.08 | 413 | 1,271 | 82,338 | Apr 05 04:55 PM | NOUGUES MAXIMO F | Chief Financial Officer | Apr 04 | Sale | 3.08 | 206 | 634 | 121,393 | Apr 05 04:52 PM | AUERBACH ALAN H | President and CEO | Apr 04 | Sale | 3.08 | 1,198 | 3,687 | 6,346,555 | Apr 05 05:41 PM | MILLER MICHAEL PATRICK | Director | Mar 16 | Sale | 2.80 | 25,653 | 71,792 | 52,858 | Mar 17 04:33 PM | NOUGUES MAXIMO F | Chief Financial Officer | Mar 02 | Sale | 2.26 | 169 | 382 | 59,423 | Mar 04 05:14 PM | HUNT DOUGLAS M | See Remarks | Mar 02 | Sale | 2.26 | 446 | 1,009 | 60,104 | Mar 04 05:11 PM | AUERBACH ALAN H | President and CEO | Mar 02 | Sale | 2.26 | 1,294 | 2,919 | 4,386,815 | Mar 04 05:07 PM | HUNT DOUGLAS M | See Remarks | Feb 02 | Sale | 2.47 | 533 | 1,317 | 60,550 | Feb 03 07:38 PM | NOUGUES MAXIMO F | Chief Financial Officer | Feb 02 | Sale | 2.48 | 199 | 494 | 59,592 | Feb 03 05:34 PM | AUERBACH ALAN H | President and CEO | Feb 02 | Sale | 2.46 | 1,316 | 3,239 | 4,388,109 | Feb 03 05:29 PM | AUERBACH ALAN H | President and CEO | Jan 03 | Sale | 3.19 | 22,875 | 72,923 | 4,389,425 | Jan 05 05:12 PM | NOUGUES MAXIMO F | Chief Financial Officer | Jan 03 | Sale | 3.19 | 7,484 | 23,871 | 59,791 | Jan 05 05:04 PM | Ludwig Jeffrey Jerome | Chief Commercial Officer | Jan 03 | Sale | 3.20 | 4,727 | 15,121 | 31,342 | Jan 05 08:32 PM | HUNT DOUGLAS M | See Remarks | Jan 03 | Sale | 3.21 | 3,707 | 11,890 | 61,083 | Jan 05 06:03 PM | Wong Alvin F | Chief Scientific Officer | Dec 02 | Sale | 2.91 | 1,131 | 3,294 | 17,152 | Dec 06 06:55 PM | HUNT DOUGLAS M | See Remarks | Dec 02 | Sale | 2.90 | 441 | 1,279 | 64,790 | Dec 06 08:33 PM | NOUGUES MAXIMO F | Chief Financial Officer | Dec 02 | Sale | 2.95 | 162 | 478 | 67,275 | Dec 06 06:37 PM | AUERBACH ALAN H | President and CEO | Dec 02 | Sale | 2.90 | 1,837 | 5,327 | 4,412,300 | Dec 06 06:31 PM | NOUGUES MAXIMO F | Chief Financial Officer | Nov 02 | Sale | 5.67 | 156 | 885 | 67,437 | Nov 03 06:22 PM | HUNT DOUGLAS M | See Remarks | Nov 02 | Sale | 5.64 | 427 | 2,409 | 65,231 | Nov 03 06:20 PM | AUERBACH ALAN H | PRESIDENT AND CEO | Nov 02 | Sale | 5.63 | 1,795 | 10,112 | 4,414,137 | Nov 03 06:17 PM | NOUGUES MAXIMO F | Chief Financial Officer | Oct 04 | Sale | 6.20 | 161 | 998 | 67,593 | Oct 06 05:20 PM | HUNT DOUGLAS M | See Remarks | Oct 04 | Sale | 6.15 | 443 | 2,726 | 65,658 | Oct 06 05:15 PM | AUERBACH ALAN H | President and CEO | Oct 04 | Sale | 6.15 | 1,858 | 11,433 | 4,415,932 | Oct 06 05:04 PM | NOUGUES MAXIMO F | Chief Financial Officer | Sep 02 | Sale | 7.51 | 155 | 1,164 | 67,754 | Sep 03 07:40 PM | HUNT DOUGLAS M | See Remarks | Sep 02 | Sale | 7.52 | 422 | 3,174 | 66,101 | Sep 07 03:36 PM | AUERBACH ALAN H | PRESIDENT AND CEO | Sep 02 | Sale | 7.60 | 1,764 | 13,403 | 4,417,790 | Sep 03 09:27 PM | NOUGUES MAXIMO F | Chief Financial Officer | Aug 02 | Sale | 7.54 | 154 | 1,161 | 67,909 | Aug 03 05:52 PM | HUNT DOUGLAS M | See Remarks | Aug 02 | Sale | 7.53 | 420 | 3,161 | 66,523 | Aug 03 05:49 PM | AUERBACH ALAN H | PRESIDENT AND CEO | Aug 02 | Sale | 7.53 | 1,764 | 13,286 | 4,419,554 | Aug 03 05:45 PM | AUERBACH ALAN H | PRESIDENT AND CEO | Jul 02 | Sale | 8.84 | 5,332 | 47,121 | 4,421,318 | Jul 06 07:42 PM | NOUGUES MAXIMO F | Chief Financial Officer | Jul 02 | Sale | 9.26 | 155 | 1,435 | 68,063 | Jul 06 05:43 PM | HUNT DOUGLAS M | See Remarks | Jul 02 | Sale | 9.15 | 1,016 | 9,298 | 66,943 | Jul 06 05:40 PM | Senderowicz Adrian | Director | Jun 11 | Sale | 11.17 | 40,993 | 457,757 | 0 | Jun 15 06:14 PM | MOYES JAY M | Director | Jun 10 | Sale | 11.36 | 25,248 | 286,860 | 6,322 | Jun 11 05:36 PM | Miller Ann Calby | Director | Jun 10 | Sale | 11.43 | 12,874 | 147,156 | 12,874 | Jun 11 04:59 PM | WILSON TROY EDWARD | Director | Jun 10 | Sale | 11.36 | 25,748 | 292,433 | 350 | Jun 11 07:30 PM | HUNT DOUGLAS M | See Remarks | Jun 02 | Sale | 10.77 | 416 | 4,481 | 67,959 | Jun 04 04:53 PM | AUERBACH ALAN H | PRESIDENT AND CEO | Jun 02 | Sale | 10.74 | 1,757 | 18,877 | 4,426,650 | Jun 04 04:49 PM |
|